Publications by authors named "Linda Lundberg"
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma.
Haematologica
November 2024
Not available.
View Article and Find Full Text PDFBackground: Glofitamab monotherapy induces durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma after two or more previous therapies, but has not previously been assessed as a second-line therapy. We investigated the efficacy and safety of glofitamab plus gemcitabine-oxaliplatin (Glofit-GemOx) versus rituximab (R)-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma.
Methods: The phase 3, randomised, open-label STARGLO trial was done at 62 centres in 13 countries in Asia and Australia, Europe, and North America.
Article Synopsis
- Some patients with a type of cancer called mantle cell lymphoma (MCL) don't have good treatment options if their cancer comes back.
- A study tested a new medicine called glofitamab, which was given after patients received another medicine to help reduce side effects.
- The results showed that many patients got better from the treatment, and while some had side effects, these were manageable with proper care.
Article Synopsis
- Glofitamab, a bispecific antibody, shows promise for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with 39% of patients achieving a complete response after treatment.
- In a phase 2 trial involving patients who had undergone at least two previous therapies, the medication was administered following obinutuzumab pretreatment to reduce side effects.
- Although the treatment was effective, 78% of complete responses were ongoing at 12 months, but 62% of patients experienced significant adverse events, primarily cytokine release syndrome.
A fixed-dose subcutaneous (s.c.) formulation of the anti-CD20 antibody, rituximab, has been developed to address safety, infusion time, and patient comfort concerns relating to intravenous (i.
View Article and Find Full Text PDFGlofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
J Clin Oncol
June 2021
Article Synopsis
- Glofitamab is a bispecific antibody targeting CD20 on B cells and CD3 on T cells, evaluated in a phase I study for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) after pretreatment with obinutuzumab to lower toxicity.
- The study involved 171 heavily pretreated patients, most of whom had aggressive lymphoma subtypes, and focused on safety, pharmacokinetics, and dosage limits of glofitamab.
- Results showed a 53.8% overall response rate with 36.8% achieving complete response; responses were durable, with manageable side effects, including cytokine release syndrome.
GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab-bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2-6; and bendamustine 70/90 mg/m D1 and D2 of C1-6.
View Article and Find Full Text PDF